/C O R R E C T I O N From Source — Portage Biotech Inc./
In its press release dated October 25, “Portage announces listing on
Canadian National Stock Exchange”, Portage Biotech Inc. conveyed
inaccurate information regarding its trading symbol. The corrected
information is provided below. We apologize for any confusion this
mistake may have created.
Portage announces listing on Canadian National Stock Exchange
TORONTO, Oct. 25, 2013 /PRNewswire/ – Portage Biotech Inc. (‘the Company”)
(OTCBB: PTGEF (“Portage”) is pleased to announce that effective October
28, 2013, the common shares of Portage will be listed for trading in US
currency on the Canadian National Stock Exchange (the “CNSX”, www.cnsx.ca) under the symbol “PBT.U”. Portage shares will also continue to be quoted and traded on Over the
Counter Bulletin Board of NASDAQ under the trading symbol “PTGEF”.
Mr. Kam Shah, CFO commented, “Portage is looking forward to this listing
on the CNSX. Listing on this recognized stock exchange will provide
additional liquidity to our shareholders, access to larger capital
markets, make our shares eligible for tax free savings and RRSP
accounts for our Canadian investors and increase our visibility and
creditability as a Canadian listed public company.”
About the CNSX:
Formerly known as the Canadian Trading and Quotation System Inc. (CNQ),
the exchange re-launched as the CNSX in November 2008 to reflect its
status as a full service, national stock exchange. CNSX’s unique model
matches enhanced disclosure and streamlined issuer regulation with
leading edge technology to meet the needs and characteristics of
emerging companies, their investors and investment dealers. CNSX is
fully recognized by the Ontario Securities Exchange Commission (OSC) as
a stock exchange and is subject to OSC regulatory requirements.
For more information on the CNSX, please visit their website: www.cnsx.ca.
Portage, a British Virgin Islands company, is engaged in researching and
developing pharmaceutical and biotech products through to clinical
“proof of concept” with an initial focus on unmet clinical needs and
orphan drugs. Following proof of concept, Portage will look to sell or
license the products to large pharmaceutical companies for further
development and commercialization.
Portage through its subsidiary, Portage Pharmaceuticals Ltd., holds an
exclusive worldwide licence in non-oncology fields and the know-how
relating to the Antennapedia protein transduction technology developed
by Trojantec. Antennapedia (“Antp”) is an unusual protein that allows
for the delivery of drugs into a cell and even into the nucleus which
is often the desired site of action. This protein coupled with a drug
may even cross the blood brain barrier. Portage is developing a
research pipeline of Antp-based drug candidates and evaluating their
function and potential as new therapeutic agents for a variety of
Portage management is looking to in license additional products to add
to its portfolio.
This news release includes forward-looking statements within the meaning
of the U.S. federal and Canadian securities laws. Any such statements
reflect Portage’s current views and assumptions about future events and
financial performance. Portage cannot assure that future events or
performance will occur. Important risks and factors that could cause
actual results or events to differ materially from those indicated in
our forward-looking statements.
Portage assumes no obligation and expressly disclaims any duty to update
the information in this News Release.
SOURCE Portage Biotech Inc.